A Phase III Randomized, Double Blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Trial Profile

A Phase III Randomized, Double Blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Sorafenib (Primary) ; Capecitabine
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms RESILIENCE
  • Sponsors Bayer
  • Most Recent Events

    • 25 Nov 2017 This trial has been completed in Germany (30 Oct 2017).
    • 14 Nov 2017 Status changed from active, no longer recruiting to completed.
    • 09 Jul 2017 Planned End Date changed from 30 Jun 2017 to 30 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top